Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EWTX Edgewise Therapeutics, Inc.

Closed Independence Day 07-02 16:00:00 EDT

39.56

+0.41

+1.05%

盘后39.57

+0.01+0.03%

16:46 EDT

High39.81	Low38.36	Vol793.04K
Open39.15	D1 Closing39.15	Amplitude3.70%
Mkt Cap4.24B	Tradable Cap2.41B	Total Shares107.27M
T/O31.06M	T/O Rate1.30%	Tradable Shares60.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EWTX","market":"US","secType":"STK","nameCN":"Edgewise Therapeutics, Inc.","latestPrice":39.56,"timestamp":1783022400000,"preClose":39.15,"halted":0,"volume":793035,"hourTrading":{"tag":"盘后","latestPrice":39.57,"preClose":39.56,"latestTime":"16:46 EDT","volume":27786,"amount":1099214.39,"timestamp":1783025190534,"change":0.01,"changeRate":0.000253,"amplitude":0.000253},"delay":0,"changeRate":0.01047254150702436,"floatShares":60849799,"shares":107270521,"eps":-1.663051,"marketStatus":"Closed Independence Day","change":0.41,"latestTime":"07-02 16:00:00 EDT","open":39.15,"high":39.81,"low":38.36,"amount":31063037,"amplitude":0.037037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.663051,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":39.15,"preHourTrading":{"tag":"盘前","latestPrice":38.9,"preClose":39.15,"latestTime":"09:27 EDT","volume":1584,"amount":62251.60392,"timestamp":1782998865094,"change":-0.25,"changeRate":-0.006386,"amplitude":0.127203},"postHourTrading":{"tag":"盘后","latestPrice":39.57,"preClose":39.56,"latestTime":"16:46 EDT","volume":27786,"amount":1099214.39,"timestamp":1783025190534,"change":0.01,"changeRate":0.000253,"amplitude":0.000253},"volumeRatio":0.506801,"impliedVol":0.7477,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/EWTX/tweets","defaultTab":"tweets","newsList":[{"id":"2648636893","title":"Edgewise Therapeutics CSO Alan J. Russell Sells 200,000 Common Shares Worth $7.88 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648636893","media":"Reuters","labels":["shareholding","insiderTrades"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2648636893?lang=en_us&edition=fundamental","pubTime":"2026-07-03 05:21","pubTimestamp":1783027315,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics CSO Alan J. Russell sells 200,000 common shares worth $7.88 millionEdgewise Therapeutics Chief Scientific Officer Alan J. Russell exercised stock options for 200,000 shares on Ju","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLqjzg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Edgewise Therapeutics CSO Alan J. Russell Sells 200,000 Common Shares Worth $7.88 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","EWTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648514637","title":"Top Edgewise Therapeutics Executive Makes Major Move With Insider Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2648514637","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648514637?lang=en_us&edition=fundamental","pubTime":"2026-07-03 10:05","pubTimestamp":1783044301,"startTime":"0","endTime":"0","summary":"New insider activity at Edgewise Therapeutics ( ($EWTX) ) has taken place on July 2, 2026. Alan J. Russell, the Chief Scientific Officer of Edgewis...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-edgewise-therapeutics-executive-makes-major-move-with-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-edgewise-therapeutics-executive-makes-major-move-with-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648485285","title":"Edgewise Therapeutics Grants Inducement Stock Options for 16,500 Shares at $40.63 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2648485285","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648485285?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:05","pubTimestamp":1782907530,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics grants inducement stock options for 16,500 shares at $40.63 eachEdgewise Therapeutics granted inducement stock options covering 16,500 common shares to two new non-executive empl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL3DL4hf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648548834","title":"Edgewise Therapeutics Reports Inducement Grants as Permitted by the NASDAQ Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2648548834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648548834?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:00","pubTimestamp":1782907209,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nTUA36M7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4539","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646332288","title":"Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2646332288","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646332288?lang=en_us&edition=fundamental","pubTime":"2026-06-26 14:21","pubTimestamp":1782454916,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics recently reported positive top-line 12-week Phase 2 Part D CIRRUS-HCM results for EDG-7500 in both obstructive and nonobstructive hypertrophic cardiomyopathy, showing clinically meaningful improvements in hemodynamics, heart failure biomarkers, patient-reported outcomes and functional status, with generally well-tolerated safety.\nA distinctive aspect of these data is the apparent preservation of systolic function across more than 700 echocardiograms while still...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/why-edgewise-therapeutics-ewtx-is-up-133-after-phase-2-edg-7","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ewtx/edgewise-therapeutics/news/why-edgewise-therapeutics-ewtx-is-up-133-after-phase-2-edg-7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4585","HCM","EWTX","BK4531","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742035","title":"Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742035","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644742035?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:02","pubTimestamp":1781708573,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics  remains a compelling cardiology story despite investor concerns around atrial fibrillation risk and the near-term catalyst path, with EDG-7500 potentially emerging as a best-in-class treatment for hypertrophic cardiomyopathy, RBC Capital Markets said.The firm said in a Tuesday note that the stock's sharp reaction to the company's 12-week data release appears to be an \"overreaction.\"RBC said it found no convincing evidence linking EDG-7500 to atrial fibrillation, noting that both atrial fibrillation events occurred in obstructive hypertrophic cardiomyopathy patients and none were observed in the nonobstructive cohort.The note said efficacy in both obstructive and nonobstructive hypertrophic cardiomyopathy was positive, with some measures potentially deepening over time.RBC also highlighted the potential for regulatory updates and pipeline developments to bridge the gap to phase 3 readouts.The firm raised its probability of success estimate for EDG-7500 to 60%.RBC ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746523","title":"Edgewise Therapeutics Is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746523","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644746523?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:30","pubTimestamp":1781699400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 08:30 ET (12:30 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644488047","title":"RBC Raises Price Target on Edgewise Therapeutics to $59 From $48, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2644488047","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644488047?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:42","pubTimestamp":1781692975,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) has an average rating of buy and mean price target of $48.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644106497","title":"Edgewise Therapeutics price target raised to $32 from $20 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2644106497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644106497?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:17","pubTimestamp":1781691430,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Paul Choi raised the firm’s price target on Edgewise Therapeutics (EWTX) to $32 from $20 and keeps a Neutral rating on the sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-32-from-20-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-32-from-20-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644764547","title":"Edgewise Therapeutics price target raised to $52 from $50 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2644764547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644764547?lang=en_us&edition=fundamental","pubTime":"2026-06-17 01:55","pubTimestamp":1781632509,"startTime":"0","endTime":"0","summary":"Leerink raised the firm’s price target on Edgewise Therapeutics (EWTX) to $52 from $50 and keeps an Outperform rating on the shares. The firm conti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-52-from-50-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-price-target-raised-to-52-from-50-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644795548","title":"Edgewise Therapeutics Reports Improvements In Heart Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644795548","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644795548?lang=en_us&edition=fundamental","pubTime":"2026-06-17 01:40","pubTimestamp":1781631600,"startTime":"0","endTime":"0","summary":"Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.","market":"us","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=260,format=auto,quality=85/files/images/story/2026/06/16/Vital-Signs-Monitor-Screen-Showing-Heart.jpeg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=260,format=auto,quality=85/files/images/story/2026/06/16/Vital-Signs-Monitor-Screen-Showing-Heart.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/06/53233008/edgewise-therapeutics-reports-improvements-in-heart-drug-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/06/53233008/edgewise-therapeutics-reports-improvements-in-heart-drug-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4531","BK4585","BK4539","BK4007","BK4588","HCM","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644769864","title":"Edgewise Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2644769864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644769864?lang=en_us&edition=fundamental","pubTime":"2026-06-17 00:07","pubTimestamp":1781626020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 12:07 ET (16:07 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644662227","title":"Buy Rating Reiterated on Edgewise Therapeutics as Strong EDG-7500 Data and Asset Sale Support Cardiovascular Pipeline; $45 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2644662227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644662227?lang=en_us&edition=fundamental","pubTime":"2026-06-16 23:55","pubTimestamp":1781625317,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on EWTX stock, giving a Buy rating on June 5. Joseph Pantginis has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-edgewise-therapeutics-as-strong-edg-7500-data-and-asset-sale-support-cardiovascular-pipeline-45-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-edgewise-therapeutics-as-strong-edg-7500-data-and-asset-sale-support-cardiovascular-pipeline-45-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX","CSII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643176352","title":"Edgewise Therapeutics falls -9.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643176352","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643176352?lang=en_us&edition=fundamental","pubTime":"2026-06-16 22:07","pubTimestamp":1781618878,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) is down -9.9%, or -$3.50 to $31.71. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-falls-9-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-falls-9-9-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643757301","title":"BUZZ-Edgewise reports mid-stage trial data for heart disease drug, shares fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2643757301","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643757301?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:46","pubTimestamp":1781613961,"startTime":"0","endTime":"0","summary":"BUZZ-Edgewise reports mid-stage trial data for heart disease drug, shares fall** Shares of Edgewise Therapeutics EWTX.O fall 10.5% to $31.50 premarket ** The drug developer says its experimental drug, EDG-7500, met the main goal in a mid-stage trial in patients with hypertrophic cardiomyopathy , a condition in which the heart muscles abnormally thickens** In the 12-week study of 53 patients with obstructive and non-obstructive HCM, the drug showed no meaningful reductions in left ventricular ejection fraction , a key measure of heart function, and no patients fell below 50%** RBC Capital Markets says the efficacy data in nonobstructive HCM may have underwhelmed some investors, but added that EDG-7500 appears competitive compared with existing cardiac myosin inhibitors ** Brokerage adds the stock's drop \"seems overdone\"** Truist says investors may be concerned about enrollment timelines, the potential need for head-to-head trials and delays before Phase 3 data** Co says late-stage trial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4N42O14S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754290","title":"Edgewise Therapeutics down 25% at $26.55 after EDG-7500 trial update","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754290?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:57","pubTimestamp":1781611055,"startTime":"0","endTime":"0","summary":"07:50 EDT Edgewise Therapeutics (EWTX) down 25% at $26.55 after EDG-7500 trial update Published first on TheFly – the ultimate source for real-time...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-down-25-at-26-55-after-edg-7500-trial-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-down-25-at-26-55-after-edg-7500-trial-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754540","title":"Edgewise Therapeutics Advances EDG-7500 to Phase 3 Following 'Positive' HCM Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754540","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754540?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:46","pubTimestamp":1781610370,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics  phase 2 Cirrus-HCM trial of EDG-7500 met key efficacy and safety endpoints in obstructive and non-obstructive hypertrophic cardiomyopathy, supporting advancement to Phase 3, the company said Tuesday.The 12-week study showed clinically meaningful improvements in echocardiogram measures, biomarkers, symptoms and functional status across both groups, including 90% of obstructive HCM patients with hemodynamic improvement and significant reductions in NT-proBNP and quality-of-life scores across cohorts.Edgewise said EDG-7500 was generally well tolerated, with no new safety signals, no meaningful reductions in LVEF below 50% and no observed relationship between drug exposure and LVEF changes.The company said it plans to initiate a Phase 3 program in Q4 2026.Edgewise Therapeutics shares were down more than 24% in premarket activity Tuesday.Price: 26.50, Change: -8.71, Percent Change: -24.74","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EWTX","BK4531","BK4585","BK4539","HCM","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643846754","title":"Edgewise Therapeutics Shares Down 26.3% Premarket After Co Reports Heart Disease Drug Mid-Stage Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2643846754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643846754?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:40","pubTimestamp":1781610048,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O0EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","EWTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643275914","title":"Edgewise says EDG-7500 posts positive 12-week Phase 2 data in hypertrophic cardiomyopathy trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643275914","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643275914?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:01","pubTimestamp":1781607715,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics released positive top-line results from a 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy.Findings have been presented as top-line data; a webcast is scheduled for today to review the results.Patients showed broad improvements in heart function, symptoms, and daily functioning across obstructive and nonobstructive disease, supporting Phase 3 advancement.Safety profile remained favorable with no meaningful signs of weakened pumping function; the drug was generally well tolerated.Phase 3 program initiation is targeted for Q4 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL2zdhzV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759642","title":"Edgewise Therapeutics Announces Positive Top-Line Data From 12-Week Phase 2 Cirrus-HCM Trial With Edg-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759642?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607611,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUAPQW1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4007","EWTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edgewisetx.com","stockEarnings":[{"period":"1week","weight":-0.0745},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.1746},{"period":"6month","weight":0.6484},{"period":"1year","weight":2.0538},{"period":"ytd","weight":0.5777}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.169596},{"month":2,"riseRate":0.2,"avgChangeRate":-0.053086},{"month":3,"riseRate":0.4,"avgChangeRate":-0.097717},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.044897},{"month":5,"riseRate":0.5,"avgChangeRate":-0.020981},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010487},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.004457},{"month":8,"riseRate":0.6,"avgChangeRate":-0.017665},{"month":9,"riseRate":0.6,"avgChangeRate":0.09895},{"month":10,"riseRate":0.6,"avgChangeRate":0.092429},{"month":11,"riseRate":0.4,"avgChangeRate":0.07088},{"month":12,"riseRate":0.2,"avgChangeRate":0.087485}],"exchange":"NASDAQ","name":"Edgewise Therapeutics, Inc.","nameEN":"Edgewise Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Edgewise Therapeutics, Inc.(EWTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Edgewise Therapeutics, Inc.,EWTX,Edgewise Therapeutics, Inc.股票,Edgewise Therapeutics, Inc.股票老虎,Edgewise Therapeutics, Inc.股票老虎国际,Edgewise Therapeutics, Inc.行情,Edgewise Therapeutics, Inc.股票行情,Edgewise Therapeutics, Inc.股价,Edgewise Therapeutics, Inc.股市,Edgewise Therapeutics, Inc.股票价格,Edgewise Therapeutics, Inc.股票交易,Edgewise Therapeutics, Inc.股票购买,Edgewise Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Edgewise Therapeutics, Inc.(EWTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Edgewise Therapeutics, Inc.(EWTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}